Innate Pharma files its 2022 universal registration document (document d'enregistrement universel) and 2022 annual report on Form 20-F
Innate Pharma announces exclusive license of antibodies to Takeda for celiac disease research program
Innate Pharma reports Full Year 2022 Financial Results and Business Update
Number of shares and voting rights of Innate Pharma as of March 1, 2023
Innate Pharma announces conference call and webcast for Full Year 2022 financial results
Innate Pharma provides update on Silicon Valley Bank exposure
Number of shares and voting rights of Innate Pharma as of February 1, 2023
Innate Pharma to participate in upcoming investor conferences
Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology
